Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLITone Dermatophagoides mezcla
- Development stage
- Unknown
- Lead developer
- ALK Abelló
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Sublingual
01
Overview
SLITone Dermatophagoides mezcla (mixture) is a sublingual immunotherapy (SLIT) allergen extract developed by ALK-Abelló. It is formulated as sublingual drops containing biological extracts of house dust mite (HDM) allergens, specifically a 50/50 mixture of *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*, the two most prevalent dust mite species. The therapy is designed to desensitize the immune system of patients suffering from house dust mite allergy, allergic asthma, and atopic dermatitis by targeting IgE-mediated allergic responses. Administered sublingually, it works by inducing immune tolerance through the development of blocking antibodies and regulatory T cells, thereby reducing allergic symptoms and the need for rescue medications over time.
- Brand names
- SLIToneSLITone ULTRASLIToneULTRAOsiris
- Other names
- SLITone Dermatophagoides mixtureSLITone house dust mite allergen extractSLITone Dermatophagoides mezcla (mixture)
02
Targets
HDM-specific IgE (House dust mite-specific immunoglobulin E)Allergen-specific CD4+ T cells recognizing Dermatophagoides-derived peptide-MHC complexes
Beyond the preview
Go deeper on SLITone Dermatophagoides mezcla.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLITone Dermatophagoides mezcla.